Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $196
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on AbbVie (NYSE:ABBV) and raised the price target from $193 to $196.
October 30, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on AbbVie and raised the price target from $193 to $196, which could positively impact the stock's performance.
The Overweight rating maintained by Morgan Stanley indicates a positive outlook for AbbVie. The increase in the price target from $193 to $196 suggests that the analyst sees further upside potential for the stock, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100